Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,069,913
  • Shares Outstanding, K 308,534
  • Annual Sales, $ 528,300 K
  • Annual Income, $ -56,110 K
  • EBIT $ 40 M
  • EBITDA $ 51 M
  • 60-Month Beta 0.46
  • Price/Sales 5.71
  • Price/Cash Flow N/A
  • Price/Book 13.10

Options Overview Details

View History
  • Implied Volatility 126.43% (+16.37%)
  • Historical Volatility 25.50%
  • IV Percentile 89%
  • IV Rank 36.71%
  • IV High 290.42% on 09/25/25
  • IV Low 31.34% on 01/24/25
  • Expected Move (DTE 14) 0.82 (8.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 120
  • Volume Avg (30-Day) 640
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 26,259
  • Open Int (30-Day) 27,996
  • Expected Range 9.08 to 10.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.08
  • Number of Estimates 4
  • High Estimate 0.11
  • Low Estimate 0.04
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.69 +13.92%
on 11/07/25
10.57 -6.34%
on 11/24/25
+0.71 (+7.73%)
since 11/05/25
3-Month
7.61 +30.09%
on 09/16/25
10.57 -6.34%
on 11/24/25
+1.91 (+23.90%)
since 09/05/25
52-Week
5.51 +79.67%
on 06/25/25
10.57 -6.34%
on 11/24/25
+0.14 (+1.43%)
since 12/05/24

Most Recent Stories

More News
Amicus Therapeutics: Q3 Earnings Snapshot

Amicus Therapeutics: Q3 Earnings Snapshot

FOLD : 9.90 (-0.50%)
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30...

FOLD : 9.90 (-0.50%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...

FOLD : 9.90 (-0.50%)
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025,...

FOLD : 9.90 (-0.50%)
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from...

FOLD : 9.90 (-0.50%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...

FOLD : 9.90 (-0.50%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END

FOLD : 9.90 (-0.50%)
TNXP : 19.64 (+0.56%)
SNGX : 1.6100 (-1.23%)
CTOR : 1.1199 (+0.89%)
AMGN : 329.89 (-3.02%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

/CNW/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging...

FOLD : 9.90 (-0.50%)
TNXP : 19.64 (+0.56%)
SNGX : 1.6100 (-1.23%)
CTOR : 1.1199 (+0.89%)
AMGN : 329.89 (-3.02%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

NetworkNewsWire Editorial Coverage

FOLD : 9.90 (-0.50%)
TNXP : 19.64 (+0.56%)
SNGX : 1.6100 (-1.23%)
CTOR : 1.1199 (+0.89%)
AMG : 273.19 (+0.55%)
AMGN : 329.89 (-3.02%)
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Amicus Therapeutics FOLD reported adjusted earnings of 1 cent per share for the second quarter of 2025, which missed the Zacks Consensus Estimate of 2 cents. The company had incurred a loss of 6 cents...

FOLD : 9.90 (-0.50%)
IMCR : 38.78 (-3.57%)
ARVN : 12.79 (+1.91%)
CRMD : 10.56 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 10.30
2nd Resistance Point 10.17
1st Resistance Point 10.04
Last Price 9.90
1st Support Level 9.78
2nd Support Level 9.65
3rd Support Level 9.52

See More

52-Week High 10.57
Last Price 9.90
Fibonacci 61.8% 8.64
Fibonacci 50% 8.04
Fibonacci 38.2% 7.44
52-Week Low 5.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar